III.
`
`
`
`
`
`IV.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CURRICULUM VITAE
`
` I.
`
`PERSONAL
`
`Thomas A. Baillie
`4775 NE 203rd St
`Seattle, WA 98155
`
` II.
`
`EDUCATION
`
`1966-1970
`1970-1973
`
`1978
`1992
`
`University of Glasgow, Glasgow, Scotland; B.Sc. (1st Class Honors) Chemistry
`
`University of Glasgow, Glasgow, Scotland; Ph.D. Organic Chemistry (Mentor: Professor
`Charles J. W. Brooks)
`
`University of London, London, England; M.Sc. Biochemistry
`University of Glasgow, Glasgow, Scotland; D.Sc. Chemistry
`
`
`
`
`POSTDOCTORAL TRAINING
`
`1973-1975
`
`Department of Physiological Chemistry, Karolinska Institute, Stockholm, Sweden (Laboratory
`of Professor Jan Sjövall)
`
`EMPLOYMENT HISTORY
`
`1975-1978
`
`1978-1981
`
`1979-1981
`
`1981-1983
`
`1983-1988
`
`Lecturer in Analytical Chemistry, Department of Clinical Pharmacology, Royal Postgraduate
`Medical School, London, England
`Assistant Research Chemist and Assistant Director, Biomedical Mass Spectrometry Resource,
`University of California Berkeley, Berkeley, CA
`Assistant Professor of Pharmaceutical Chemistry in Residence, University of California San
`Francisco, San Francisco, CA
`Assistant Professor of Medicinal Chemistry, School of Pharmacy, University of Washington,
`Seattle, WA
`Associate Professor of Medicinal Chemistry, School of Pharmacy, University of Washington,
`Seattle, WA
`Visiting Professor, Department of Clinical Pharmacology, Huddinge University Hospital,
`Stockholm, Sweden
`Professor of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle,
`WA
`Affiliate Professor of Medicinal Chemistry, School of Pharmacy, University of Washington,
`Seattle, WA
`Executive Director, Preclinical Drug Metabolism, Merck Research Laboratories, West Point,
`PA
`Vice President, Drug Metabolism, Merck Research Laboratories, West Point, PA
`Vice President and Global Head, Drug Metabolism and Pharmacokinetics, Merck Research
`Laboratories, West Point, PA
`Virginia and Prentice Bloedel Professor of Medicinal Chemistry, School of Pharmacy,
`University of Washington, Seattle, WA
`Dean, School of Pharmacy, University of Washington, Seattle, WA
`2008-2014
`Chair, Board of Health Sciences Deans, University of Washington, Seattle, WA
`2011-2014
`Vice Provost, Strategic Initiatives, University of Washington, Seattle, WA
`2012-2014
`2014-present Dean Emeritus, University of Washington, Seattle, WA
`
`1988-1989
`
`1988-1994
`
`1994-2008
`
`1994-1996
`
`1996-2007
`2007-2008
`
`2008-2014
`
`1 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 2
`
`
`
`
`
`V.
`
`
`VI.
`
`FEDERAL GRANT SUPPORT
`
`Continuous funding (1981-1994) as Principal Investigator of National Institutes of Health R01 grants
`DK30699, GM32165 and ES05500.
`
`P51 OD01425 Washington National Primate Research Center, T. A. Baillie PI, 2012-2013, Direct Costs for 5-
`year period $9,737,673.
`
`
`
`
`THESES AND DISSERTATIONS DIRECTED
`
`University of London
`
`Roy Clare. M.Sc. in Analytical Chemistry, 1977.
`Dissertation title: "Development of a Method for the Determination of the β-Andrenoceptor Stimulant
`Terbutaline in Body Fluids."
`
`Helen Hughes. Ph.D. in Clinical Pharmacology, 1980.
`Dissertation title: "The Synthesis and Metabolism of Clonidine and Structurally Related Imidazolines."
`
`University of Washington
`
`Yan (Louis) Leung. Ph.D. in Medicinal Chemistry, 1986.
`Dissertation title: "Studies on the Biotransformation and Pharmacology of Ketamine and its Metabolites."
`
`Susan Bjorge. Ph.D. in Medicinal Chemistry, 1988.
`Dissertation title: "Metabolic Studies with the Antiepileptic Drug Valproic Acid."
`
`Hope Barnes. Ph.D. in Medicinal Chemistry, 1991.
`Dissertation title: "Stereochemical Studies on the Formation and Metabolic Fate of 2-n-Propyl-4-Pentenoic
`Acid, a Hepatotoxic Metabolite of the Antiepileptic Drug Valproic Acid."
`
`Kanyin Zhang. Ph.D. in Medicinal Chemistry, 1992.
`Dissertation title: "Metabolic Disposition of the Novel Antiepileptic Agent Stiripentol and Related
`Compounds."
`
`Mark Grillo. Ph.D. in Medicinal Chemistry, 1993.
`Dissertation title: "Mechanistic Studies on the Metabolic Activation of Valproic Acid."
`
`Margaret Davis. Ph.D. in Medicinal Chemistry, 1994.
`Dissertation title: "Applications of Ionspray Tandem Mass Spectrometry to Studies on the Biological
`Chemistry of Isocyanates."
`
`Lixia Jin. Ph.D. in Medicinal Chemistry, 1996.
`Dissertation title: "Application of Ionspray Tandem Mass Spectrometry to Mechanistic Studies on the
`Bioactivation of Xenobiotics."
`
`Kathleen Schultz. Ph.D. in Medicinal Chemisty, 1997.
`Dissertation title: "Glutathione Dependent Metabolism and Toxicity of Isocyanates."
`
`
`
`2 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 3
`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`
`
`Michelle Wahlin. Ph.D. in Medicinal Chemisty, 2014. (Jointly supervised with Sidney D. Nelson)
`Dissertation title: “Defining the Relationship between the Bioactivation of Lapatinib by CYP3A and
`Lapatinib-Induced Hepatotoxicity.”
`
`
`
` VII. MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES
`
`
`Royal Society of Chemistry (Professional Qualifications FRSC, CChem, CSci)
`American Chemical Society (Division of Chemical Toxicology, Executive Committee, 2000-2002 and
`2013-2014; Nominating Committee, 2009-2010; Editor Search Committee for Chemical Research in
`Toxicology, 2012; Chair, Awards Committee, 2013-2014)
`American Society for Mass Spectrometry (Secretary 1993-1995)
`International Society for the Study of Xenobiotics (Councilor 1991-1993 and 2012-2015, Secretary Elect
`1996-1997, Secretary 1998-1999, President Elect 2016-2017)
`International Isotope Society (Trustee 1987-1990 and 1992-1994, President 1991, IIS Council
` Member 2005-2008)
`PhRMA Drug Metabolism Technical Group, Member (1998-2000), Chair-Elect (2001), Chair (2002-
`
`2003), and Past Chair (2004-2005)
`Society of Toxicology
`
`Editor, Chemico-Biological Interactions, 1990-1997.
`Editorial Advisory Board, Modern Mass Spectrometry, 1991-1998.
`Editorial Board, Rapid Communications in Mass Spectrometry, 1986-1997.
`Advisory Board, Journal of Labelled Compounds and Radiopharmaceuticals, 1987-2008.
`Editorial Advisory Board, Chemical Research in Toxicology, 1990-1992, 1995-2001.
`Editorial Advisory Board, Biological Mass Spectrometry, 1990-1994.
`Editorial Advisory Board, Life Sciences, 1993-2001.
`Editorial Advisory Board, Drug Metabolism and Disposition, 1994-present.
`Editorial Advisory Board, Mass Spectrometry Reviews, 1994-1996.
`Editorial Advisory Board, Journal of Mass Spectrometry, 1994-1997.
`Editorial Advisory Board, Drug Metabolism Reviews, 2002-present.
`Editorial Advisory Board, Drug Discovery Today: Technologies, 2008-present.
`
`HONORS AND AWARDS
`
`Undergraduate (University of Glasgow): Merit Award in Physics, 1967. Merit Awards in Chemistry: 1967,
`1968, 1969. B.Sc. with First Class Honors, 1970.
`
`Postgraduate: Research Studentship from the Science Research Council, U.K., 1970-1973.
`
`Postdoctoral: Royal Society Postdoctoral Fellowship, 1973-1975.
`
`Co-Recipient of the “Best Paper Award” for an article published in Drug Metabolism and Disposition.
`American Society for Pharmacology and Experimental Therapeutics, 1986, 1993, and 2001.
`
`Visiting Professor, Shanghai Second Medical College, People’s Republic of China, October 1984.
`
`Searle Visiting Professor, University of British Columbia, Vancouver, B.C., Canada, November 1986.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` IX.
`
`
`
`
`
`
`
`
`VIII. EDITORIAL BOARD MEMBERSHIPS
`
`3 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 4
`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`
`
`
`LACDR Distinguished Lecturer, Leiden, The Netherlands, 1998.
`
`Fogarty Senior International Fellowship, 1988-1989.
`
`Graduate Students’ Choice Lecturer, University of Illinois at Chicago, School of Pharmacy, 2003.
`
`Lubomir S. Hnilica Toxicology & Biochemistry Student Lecturer, Vanderbilt University, 2009.
`
`IIS Lifetime Achievement Award, International Isotope Society, 2009.
`
`Elected Fellow, Japanese Society for the Study of Xenobiotics, 2010.
`
`Elected Fellow, American Chemical Society, 2011.
`
`Founder’s Award, American Chemical Society Division of Chemical Toxicology, 2012.
`
`North American Scientific Achievement Award, International Society for the Study of Xenobiotics, 2014.
`
`
`
`PROFESSIONAL ACTIVITIES
`
`X.
`
`
`
`
`
`
`
`Science Advisor, Food and Drug Administration, San Francisco Regional Laboratories, San Francisco, CA,
`1980-1981.
`
`
`Ad hoc Member, Biomedical Engineering and Technology Review Group, National Institutes of Health, 1984.
`
`Special Reviewer, Metallobiochemistry Study Section, National Institutes of Health, 1985.
`
`Ad hoc Member, Special Study Section, Division of Research Resources, National Institutes of Health, 1985-
`1987, 1990, 1993, 1995, 1998.
`
`
`Member, Site Visit Teams, National Institute of Environmental Health Sciences and National Institute of Child
`Health and Human Development, 1986.
`
`
`Member (1985-1987) and Chairman (1987-1989), Developmental Therapeutics Contracts Review Committee,
`National Cancer Institute, National Institutes of Health.
`
`
`Ad hoc Member, Contracts Technical Review Group, National Cancer Institute, National Institutes of Health,
`1988.
`
`
`Research Grant Proposal Reviewer, Canadian Medical Research Council and British Columbia Health Care
`Research Foundation, 1986 – 1994.
`
`
`Research Grant Proposal Reviewer, National Health and Medical Research Council of Australia, 1992.
`
`Research Grant Proposal Reviewer, U.S. Department of Energy, 1987.
`
`Research Grant Proposal Reviewer, National Science Foundation, 1990-1992.
`
`Research Grant Proposal Reviewer, Hong Kong Research Grants Council, 1994.
`
`
`4 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 5
`
`External Examiner, Ph.D. Thesis, University of Saskatchewan, Saskatoon, Saskatchewan, 1990.
`
`External Examiner, Ph.D. Thesis, University of New South Wales, Sydney, Australia, 1992.
`
`External Examiner, Ph.D. Thesis, Flinders University of South Australia, Bedford Park, Australia, 1993.
`
`Consultant, Procter and Gamble Co., 1987-1994.
`
`Consultant, Merck Sharp & Dohme Research Laboratories, 1993-1994.
`
`Consultant, Battelle Pacific Northwest Laboratories, 1994.
`
`Vice Chair (1993) and Chair (1994), Gordon Research Conference on Drug Metabolism, Plymouth, NH.
`
`Ph.D. Thesis Opponent, Karolinska Institute, Stockholm, Sweden, September, 1997.
`
`Member, Advisory Board for the Graduate School, Philadelphia College of Pharmacy & Science, 1997 - 1998.
`
`Member, External Advisory Board, Southwest Environmental Health Sciences Center, University of Arizona,
`Tucson, AZ, 1996-2000.
`
`
`Member, Drug Metabolism Technical Group, PhRMA, 1998-2005.
`
`Member, Objective Review Committee, U.S. Food and Drug Administration, 1999.
`
`Member, National Advisory Committee, University of California San Francisco Mass Spectrometery Facility,
`1990-present.
`
`
`Member, External Advisory Board, MIT Center for Environmental Health Sciences, Massachusetts Institute of
`Technology, 2003-2005.
`
`
`Member, Scientific Advisory Board, Advion Biosciences, Inc., Ithaca, NY, 2001-2006.
`
`Member, External Advisory Board, Biomedical Resource for Accelerator Mass Spectrometry, Lawrence
`Livermore National Laboratory, 2000-present.
`
`
`Member, External Advisory Committee, Clinical & Translational Science Award (CTSA) and Institute for
`Translational Medicine & Therapeutics (ITMAT), University of Pennsylvania, 2006-present.
`
`Member, International Advisory Board, 14th International Symposium on Microsomes and Drug Oxidations,
`Sapporo, Japan, July, 2002.
`
`
`Member, Scientific Organizing Committee, 11th North American ISSX Meeting, Orlando, FL, October, 2002.
`
`Visiting Professor, Peking Union Medical Center, Beijing, People’s Republic of China, July, 2002.
`
`Member, International Advisory Board, 15th International Symposium on Microsomes and Drug Oxidations,
`Mainz, Germany, July 2004.
`
`
`Member, Corporate Advisory Board, University of Washington School of Pharmacy, 2002-2008.
`
`Member, Scientific Program Committee, 7th International Symposium on Biological Reactive Intermediates,
`Tuscon, AZ, January 4-7, 2006.
`
`
`
`
`
`
`
`
`
`
`
`5 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 6
`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`
`
`
`Member, International Advisory Committee, 16th International Symposium on Microsomes and Drug
`Oxidation, Budapest, Hungary, September 3-7, 2006.
`
`
`Member, International Advisory Committee, 17th International Symposium on Microsomes and Drug
`Oxidations, Saratoga Springs, NY, July 6-10, 2008.
`
`
`Member, External Advisory Committee, Center of Excellence in Environmental Toxicology, University of
`Pennsylvania, 2006-present.
`
`
`Member, Scientific Advisory Board, MRC Centre for Drug Safety Science, University of Liverpool, UK,
`2009-present.
`
`
`Member, Grant Review Panel, University of California Multi-Campus Research Programs Initiative, 2009.
`
`Ph.D. Thesis Opponent, University of Göteborg, Sweden, May, 2010.
`
`Member, Scientific Program Committee, 8th International Symposium on Biological Reactive Intermediates,
`Barcelona, Spain, July 15-18, 2010.
`
`
`Member, International Scientific Advisory Committee, 19th International Microsomes & Drug Oxidations / 12th
`European ISSX Joint Meeting, Noordwijk, The Netherlands, June 17-21, 2012.
`
`
`Secretary, Executive Committee, Board of Trustees, Museum of Flight, Seattle, WA, 2013-2014.
`
`Chair, Exhibits Committee, Board of Trustees, Museum of Flight, Seattle, WA, 2014-present.
`
`Member, Board of Trustees (2011-2012), and Vice President (2013-2014), University of Washington Club.
`
`Member, External Scientific Panel, Drug Safety and Metabolism, AstraZeneca, 2013 and 2015.
`
`Member, External Scientific Advisory Committee, Medicines for Malaria Venture, 2014-2017.
`
`Member, Organizing Committee, 11th International Symposium on Mass Spectrometry in the Health and Life
`Sciences: Molecular and Cellular Proteomics,” San Francisco, CA, August 17-21, 2014.
`
`
`Member, International Scientific Advisory Board, 11th International ISSX Meeting, Busan, Korea, June, 2016.
`
`Member, International Scientific Advisory Committee, 21st International Symposium on Microsomes & Drug
`Oxidations, Davis, CA, October 2-6, 2016.
`
`
`External Examiner, Ph.D. Thesis, National University of Singapore, 2015.
`
`
`PUBLICATIONS
`
`
`
`XI.
`
`
`
`
`
`FULL PAPERS
`
`
`T. A. Baillie, C. J. W. Brooks and B. S. Middleditch, "Comparison of Corticosteroid Derivatives by Gas
`Chromatography-Mass Spectrometry," Anal. Chem., 44, 30-37, 1972.
`
`6 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 7
`
`T. A. Baillie, C. J. W. Brooks and E. C. Horning, "O-Butyloximes and O-Pentyloximes as Derivatives for the
`Study of Ketosteroids by Gas Chromatography," Anal. Letters, 5, 351-361, 1972.
`
`
`R. A. Anderson, E. M. Chambaz, G. Defaye, C. Madani, T. A. Baillie and C. J. W. Brooks, "Steroids in the
`Human Newborn: Lipophilic Gel Separation and Gas Phase Analysis," J. Chromatogr. Sci., 12, 636-641,
`1974.
`
`T. A. Baillie, J. E. Herz and J. Sjövall, "Synthesis of 5α-Pregnane-3α,20α-diol and of 5α-Pregnane-3β,20α-diol
`Labeled Specifically at the 20β-Position," J. Labelled Comp., 10, 549-556, 1974.
`
`
`T. A. Baillie, H. Eriksson, J. E. Herz and J. Sjövall, "Specific Deuterium Labeling and Computerized Gas
`Chromatography-Mass Spectrometry in Studies on the Metabolism of a Steroid Sulphate in the Rat," Eur.
`J. Biochem., 55, 157-165, 1975.
`
`T. A. Baillie and H. Eriksson, "Role of the Site of Sulphoconjugation on the Formation of Hydroxylated
`Corticosterone Metabolites in the Rat," FEBS Letters, 58, 170-174, 1975.
`
`T. A. Baillie, J. Sjövall and K. Sjövall, "Origin of 5α-Pregnane-3α,20α,21-triol 3-Sulphate in Pregnant
`Women," FEBS Letters, 60, 145-148, 1975.
`
`T. A. Baillie, J. Sjövall and J. E. Herz, "Synthesis of Specifically Deuterium-Labeled Pregnanolone and
`Pregnanediol Sulphates for Metabolic Studies in Humans," Steroids, 26, 438-457, 1975.
`
`
`T. A. Baillie, R. A. Anderson, K. Sjövall and J. Sjövall, "Identification and Quantitation of 16α-Hydroxy-C21
`Steroid Sulphates in Plasma from Pregnant Women," J. Steroid Biochem., 7, 203-209, 1976.
`
`A. R. Brash, T. A. Baillie, R. A. Clare and G. H. Draffan, "Quantitative Determination of the Major
`Metabolite of Prostaglandins F1α and F2α in Human Urine Based on Stable Isotope Dilution and Gas
`Chromatography-Mass Spectrometry," Biochem. Med., 16, 77-94, 1976.
`
`A. R. Brash, G. H. Draffan, R. A. Clare and T. A. Baillie, "A New Method for the Determination of the Major
`Metabolite of Prostaglandin F2α in Human Urine Based on Stable Isotope Dilution and Gas
`Chromatography-Mass Spectrometry," Biochem. Soc. Trans., 4, 706-708, 1976.
`
`
`D. Gompertz, P. Tippett, K. Bartlett and T. A. Baillie, "Identification of Urinary Metabolites of Sodium
`Dipropylacetate in Man: Potential Sources of Interference in Organic Acid Screening Procedures," Clin.
`Chim. Acta, 74, 153-160, 1977.
`
`S. Murray, T. A. Baillie and D. S. Davies, "A Non-Enzymic Procedure for the Quantitative Analysis of (3-
`Methoxy-4-sulphooxypheny)ethylene Glycol (MHPG Sulphate) in Human Urine Using Stable Isotope
`Dilution and Gas Chromatography-Mass Spectrometry," J. Chromatogr. (Biomed. Appl.), 143, 541-551,
`1977.
`
`J. A. Trimbrell, J. M. Wright and T. A. Baillie, "Monoacetylhydrazine as a Metabolite of Isoniazid in Man,"
`Clin. Pharmacol. Ther., 22, 602-608, 1977.
`
`T. A. Baillie, M. Karls and J. Sjövall, "Synthesis of Deuterium-Labeled Lithocholic Acid," J. Labelled Compd.
`Radiopharm., 14, 849-859, 1978.
`
`A. R. Brash and T. A. Baillie, "A Comparison of t-Butyldimethylsilyl and Trimethylsilyl Ether Derivatives for
`the Characterization of Urinary Metabolites of Prostaglandin F2α by Gas Chromatography-Mass
`Spectrometry," Biomed. Mass Spectrom., 5, 346-356, 1978.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 8
`
`S. Murray and T. A. Baillie, "Direct Derivatization of Sulphate Esters for Analysis by Gas Chromatography
`Mass Spectrometry," Biomed. Mass Spectrom., 6, 82-89, 1979.
`
`A. R. Brash and T. A. Baillie, "The Identification of 5β,7α-Dihydroxy-11-oxotetranorprostane-l,16-dioic Acid
`as a Urinary Metabolite of Prostaglandin F2α in the Rat," Biochim. Biophys. Acta, 572, 371-375, 1979.
`
`R. A. Clare, D. S. Davies and T. A. Baillie, "Analysis of Terbutaline in Biological Fluids by Gas
`Chromatography-Electron Impact Mass Spectrometry," Biomed. Mass Spectrom., 6, 31-37, 1979.
`
`H. Hughes and T. A. Baillie, "Synthesis of Clonidine and 1,3-Dimethylclonidine Labelled at Specific Positions
`with Deuterium and Carbon-13," J. Labelled Compd. Radiopharm., 17, 871-888, 1980.
`
`G. F. Gibbons, C. R. Pullinger, T. A. Baillie and R. A. Clare, "Metabolism of Hydroxy Sterols by Rat Liver,"
`Biochim. Biophys. Acta, 619, 98-106, 1980.
`
`S. Murray, A. R. Boobis, T. A. Baillie, D. S. Davies and H. Frank, "Stereoselective Excretion of 3-Methoxy-4-
`sulphooxyphenylethylene Glycol Sulphate in the Dog," Naunyn Schmiedeberg's Archiv Pharmacol., 314,
`89-96, 1980.
`
`T. A. Baillie, T. Curstedt, K. Sjövall and J. Sjövall, "Production Rates and Metabolism of Sulphates of 3β-
`Hydroxy-5α-Pregnane Dervatives in Pregnant Women," J. Steroid Biochem., 13, 1473-1488, 1980.
`
`S. D. Nelson, Y. Vaishnav, H. Kambara and T. A. Baillie, "Comparative Electron Impact, Chemical Ionization
`and Field Desorption Mass Spectra of Some Thioether Metabolites of Acetaminophen," Biomed. Mass
`Spectrom., 8, 244-251, 1981.
`
`J. D. Adams, A. J. Trevor, N. Castagnoli and T. A. Baillie, "Studies on the Biotransformation of Ketamine. I.
`Identification of Metabolites Produced in vitro from Rat Liver Microsomal Preparations." Biomed. Mass
`Spectrom. 8, 527-538, 1981.
`
`S. Murray, T. A. Baillie and D. S. Davies, "Synthesis of 1-(3-Trideuteromethoxy-4-hydroxyphenyl)-[1,2,2-
`2H3]ethylene glycol([2H6-MHPG])," J. Labelled Compd. Radiopharm., 18, 1135-1140, 1981.
`
`D. Ward, A. Kalir, A. Trevor, J. Adams, T. Baillie and N. Castagnoli, "Metabolic Formation of Iminium
`Species: Metabolism of Phencyclidine," J. Med. Chem., 25, 491-492, 1982.
`
`D. P. Ward, A. J. Trevor, A. Kalir, J. D. Adams, T. A. Baillie and N. Castagnoli, "Metabolism of
`Phencyclidine: The Role of Iminium Ion Formation in Covalent Binding to Rabbit Microsomal Protein,"
`Drug Metab. Dispos., 10, 690-695, 1982.
`
`A. J. Streeter, D. C. Dahlin, S. D. Nelson and T. A. Baillie, "The Covalent Binding of Acetaminophen to
`Protein. Evidence for Cysteine Residues as Major Sites of Arylation In Vitro," Chem.-Biol. Interact., 48,
`349-366, 1984.
`
`K. S. Prickett and T. A. Baillie, "Metabolism of Valproic Acid by Hepatic Microsomal Cytochrome P-450",
`Biochem. Biophys. Res. Commun., 122, 1166-1173, 1984.
`
`K. S. Prickett and T. A. Baillie, "Evidence for the in vitro Metabolism of Allylisopropyl-acetamide to Reactive
`Intermediates. Mechanistic Studies with Oxygen-18", Biomed. Mass Spectrom., 11, 320-331, 1984.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 9
`
`A. J. Streeter, S. M. Bjorge, D. B. Axworthy, S. D. Nelson and T. A. Baillie, "The Microsomal Metabolism
`and Site of Covalent Binding to Protein of 3α-Hydroxyacetanilide, a Non-Hepatotoxic Positional Isomer
`of Acetaminophen," Drug Metab. Dispos., 12, 565-576, 1984.
`
`T. Woolf, A. Trevor, T. Baillie and N. Castagnoli, Jr., "Synthesis of (Z)- and (E)-6-Hydroxyketamine," J. Org.
`Chem., 49, 3305-3310, 1984.
`
`A. W. Rettenmeier, K. S. Prickett, W. P. Gordon, S. M. Bjorge, S.-L. Chang, R. H. Levy and T. A. Baillie,
`"Studies on the Biotransformation in the Perfused Rat Liver of 2-n-Propyl-4-pentenoic Acid, a Metabolite
`of the Antiepileptic Drug Valproic Acid", Drug Metab. Dispos., 13, 81-96, 1985.
`
`K.-J. Hoffmann, A. J. Streeter, D. B. Axworthy and T. A. Baillie, "Structural Characterization of the Major
`Covalent Adduct Formed In Vitro Between Acetaminophen and Bovine Serum Albumin," Chem.-Biol.
`Interact., 53, 155-172, 1985.
`
`K.-J. Hoffmann, A. J. Streeter, D. B. Axworthy and T. A. Baillie, "Identification of the Major Covalent
`Adduct formed In Vitro and In Vivo between Acetaminophen and Mouse Liver Proteins", Mol.
`Pharmacol., 27, 566-573, 1985.
`
`
`A. J. Streeter and T. A. Baillie, "2-Acetamido-p-benzoquinone: A Reactive Arylating Metabolite of 3α-
`Hydroxyacetanilide", Biochem. Pharmacol., 34, 2871-2876, 1985.
`
`J. Weissman, A. Trevor, K. Chiba, L. A. Peterson, P. Caldera, N. Castagnoli, Jr. and T. Baillie, "Metabolism
`of the Nigrostriatal Toxin l-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) by Liver Homogenate
`Fractions", J. Med. Chem., 28, 997-1001, 1985.
`
`
`S. M. Bjorge and T. A. Baillie, "Inhibition of Medium-Chain Fatty Acid β-Oxidaton In Vitro by Valproic Acid
`and its Unsaturated Metabolite, 2-n-Propyl-4-Pentenoic Acid," Biochem. Biophys. Res. Commun., 132,
`245-252, 1985.
`
`K. S. Prickett and T. A. Baillie, "Metabolism of Unsaturated Derivatives of Valproic Acid in Rat Liver
`Microsomes and Destruction of Cytochrome P-450", Drug Metab. Dispos., 14, 221-229, 1986.
`
`
`A. E. Rettie, A. W. Rettenmeier, B. K. Beyer, T. A. Baillie and M. R. Juchau, "Valproate Hydroxylation by
`Human Fetal Tissues and Embryotoxicity of Metabolites," Clin. Pharmacol. Ther., 40, 172-177, 1986.
`
`A. W. Rettenmeier, W. P. Gordon, K. S. Prickett, R. H. Levy, J. S. Lockard, K. E. Thummel and T. A. Baillie,
`"Metabolic Fate of Valproic in the Rhesus Monkey. Formation of a Toxic Metabolite, 2-n-Propyl-4-
`pentenoic Acid," Drug Metab. Dispos., 14, 443-453, 1986.
`
`A. W. Rettenmeier, W. P. Gordon, K. S. Prickett, R. H. Levy and T. A. Baillie, "Biotransformation and
`Pharmacokinetics in the Rhesus Monkey of 2-n-Propyl-4-Pentenoic Acid, a Toxic Metabolite of Valproic
`Acid," Drug Metab. Dispos., 14, 454-464, 1986.
`
`L. Y. Leung and T. A. Baillie, "Comparative Pharmacology in the Rat of Ketamine and its two Principal
`Metabolites, Norketamine and (Z)-6-Hydroxynorketamine", J. Med. Chem., 29, 2396-2399, 1986.
`
`T. A. Moreland, J. Astoin, F. Lepage, F. Tombret, R. H. Levy and T. A. Baillie, "The Metabolic Fate of
`Stiripentol in Man," Drug Metab. Dispos., 14, 654-662, 1986.
`
`A. E. Rettie, A. W. Rettenmeier, W. N. Howald and T. A. Baillie, "Cytochrome P-450-Catalyzed Formation of
`Δ4-VPA, a Toxic Metabolite of the Antiepileptic Drug Valproic Acid," Science, 235, 890-893, 1987.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`9 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 10
`
`L. K. Keefer, A. J. Streeter, L. Y. Leung, W. C. Perry, H. S.-W. Hu and T. A. Baillie, "Pharmacokinetic and
`Deuterium Isotope Effect Studies on the Metabolism of Formaldehyde and Formate to Carbon Dioxide in
`Rats In Vivo," Drug Metab. Dispos., 15, 300-304, 1987.
`
`A. W. Rettenmeier, W. P. Gordon, H. Barnes and T. A. Baillie, "Studies on the Metabolic Fate of Valproic
`Acid in the Rat Using Stable Isotope Techniques," Xenobiotica, 17, 1147-1157, 1987.
`
`
`M. D. Threadgill, D. B. Axworthy, T. A. Baillie, P. B. Farmer, K. C. Farrow, A. Gescher, P. Kestell, P. G.
`Pearson and A. J. Shaw, "The Metabolism of N-Methylformamide in Mice: Primary Kinetic Deuterium
`Isotope Effect and Identification of S-(N-Methylcarbamoyl)glutathione as a Metabolite", J. Pharmacol.
`Exp. Ther., 242, 312-319, 1987.
`
`K.-J. Hoffmann and T. A. Baillie, "The Use of Alkoxycarbonyl Derivatives for the Mass Spectral Analysis of
`Drug-Thioether Metabolites. Studies with the Cysteine, Mercapturic Acid and Glutathione Conjugates of
`Acetaminophen," Biomed. Environ. Mass Spectrom., 15, 637-647, 1988.
`
`G. A. Pascoe, C. J. Calleman and T. A. Baillie, "Identification of S-(2,5-Dihydroxyphenyl) Cysteine and S-
`(2,5-Dihydroxyphenyl)-N-Acetylcysteine as Urinary Metabolites of Acetaminophen in the Mouse.
`Evidence for p-Benzoquinone as a Reactive Intermediate in Acetaminophen Metabolism," Chem.-Biol.
`Interact., 68, 85-98, 1988.
`
`
`D. B. Axworthy, K.-J. Hoffmann, A. J. Streeter, C. J. Calleman, G. A. Pascoe and T. A. Baillie, "Covalent
`Binding of Acetaminophen to Mouse Hemoglobin. Identification of Major and Minor Adducts formed In
`Vivo and Implications for the Nature of the Arylating Metabolites," Chem.-Biol. Interact., 68, 99-116,
`1988.
`
`P. G. Pearson, M. D. Threadgill, W. N. Howald and T. A. Baillie, "Applications of Tandem Mass
`Spectrometry to the Characterization of Derivatized Glutathione Conjugates. Studies with S-(N-
`Methylcarbamoyl)glutathione, a Metabolite of the Antineoplastic Agent N-Methyl-formamide," Biomed.
`Environ. Mass Spectrom., 16, 51-56, 1988.
`
`D. J. Porubek, M. P. Grillo and T. A. Baillie, "The Covalent Binding to Protein of Valproic Acid and its
`Hepatotoxic Metabolite, 2-n-Propyl-4-pentenoic Acid, in Rats and in Isolated Rat Hepatocytes," Drug
`Metab. Dispos., 17, 123-130, 1989.
`
`A. E. Rettie, M. Boberg, A. W. Rettenmeier and T. A. Baillie, "Cytochrome P-450-catalyzed Desaturation of
`Valproic Acid In Vitro. Species Differences, Induction Effects, and Mechanistic Studies," J. Biol. Chem.,
`263, 13733-13738, 1988.
`
`D. J. Porubek, H. Barnes, L. J. Theodore and T. A. Baillie, "Enantioselective Synthesis and Preliminary
`Metabolic Studies of the Optical Isomers of 2-n-Propyl-4-pentenoic Acid, a Hepatotoxic Metabolite of
`Valproic Acid," Chem. Res. Toxicol., 1, 343-348, 1988.
`
`A. W. Rettenmeier, W. N. Howald, R. H. Levy, D. J. Witek, W. P. Gordon, D. J. Porubek and T. A. Baillie,
`"Quantitative Metabolic Profiling of Valproic Acid in Humans Using Automated GC/MS Techniques,"
`Biomed. Environ. Mass Spectrom., 18, 192-199, 1989.
`
`N. E. MacKenzie, E. A. Van de Waa, P. R. Gooley, J. F. Williams, J. L. Bennett, S. M. Bjorge, T. A. Baillie
`and T. G. Geary, "Comparison of Glycolysis and Glutaminolysis in Onchocerca volvulus and Brugia
`pahangi by 13C NMR Spectroscopy", Parasitology, 99, 427-435, 1989.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 11
`
`D. J. Porubek, H. Barnes, G. P. Meier, L. J. Theodore and T. A. Baillie, "Enantiotopic Differentiation during
`the Biotransformation of Valproic Acid to the Hepatotoxic Olefin, 2-n-Propyl-4-pentenoic Acid", Chem.
`Res. Toxicol., 2, 35-40, 1989.
`
`T. A. Baillie, W. J. Adams, D. G. Kaiser, L. S. Olanoff, G. W. Halstead, H. Harpootlian and G. J. Van
`Giessen, "Mechanistic Studies on the Metabolic Chiral Inversion of (R)-Ibuprofen in Man", J. Pharmacol.
`Exp. Ther. 249, 517-523, 1989.
`
`L. Y. Leung and T. A. Baillie, "Studies on the Biotransformation of Ketamine. II. Quantitative Significance
`of the N-Demethylation Pathway in Rats In Vivo Determined by a Novel Stable Isotope Technique",
`Biomed. Environ. Mass Spectrom. 18, 401-404, 1989.
`
`C. J. Decker, M. S. Rashed, T. A. Baillie, D. Maltby and M. A. Correia, "Oxidative Metabolism of
`Spironolactone: Evidence for the Involvement of Electrophilic Thiosteroid Species in Drug-Mediated
`Destruction of Rat Hepatic Cytochrome P-450," Biochemistry, 28, 5128-5136, 1989.
`
`
`T. A. Baillie, P. G. Pearson, M. S. Rahsed and W. N. Howald, "The Use of Mass Spectrometry in the Study of
`Chemically-Reactive Drug Metabolites. Applications of MS/MS and LC/MS to the Analysis of
`Glutathione- and Related S-Linked Conjugates of N-Methylformamide," J. Pharmaceut. Biomed. Anal. 7,
`1351-1360, 1989.
`
`
`D.-H. Han, P. G. Pearson and T. A. Baillie, "Synthesis and Characterization of Isotopically-Labelled Cysteine
`and Glutathione Conjugates of Methylisocyanate," J. Labelled Comp. Radiopharm. 27, 1371-1382, 1989.
`
`K. M. Koch, K. S. Prickett, A. W. Rettenmeier, T. A. Baillie and R. H. Levy, "Beta-Oxidation of Valproic
`Acid. II. Effects of Fasting, Glucose and Clofibrate in the Rat," Epilepsia, 30, 790-796, 1989.
`
`M.S. Rashed, P.G. Pearson, D.-H. Han and T.A. Baillie, "Application of Thermospray Liquid
`Chromatography/Mass Spectrometry to Studies on the Formation of Glutathione and Cysteine
`Conjugates from Monomethylcarbamate Metabolites of Bambuterol," Rapid Commun. Mass Spectrom. 3,
`360-363, 1989.
`
`L. Bertilsson, T. A. Baillie and J. Reviriego, "Factors Influencing the Metabolism of Diazepam," Pharmacol.
`Ther. 45, 85-91, 1990.
`
`K. Zhang, F. LePage, G. Cuvier, J. Astoin, M. S. Rashed and T.A. Baillie "The Metabolic Fate of Stiripentol
`in the Rat. Studies on Cytochrome P-450-Mediated Methylenedioxy Ring Cleavage and Side-Chain
`Isomerism," Drug Metab. Dispos. 18, 794-803, 1990.
`
`S. M. Sanins, W. J. Adams, D. G. Kaiser, G. W. Halstead and T. A. Baillie, "Studies on the Metabolism and
`Chiral Inversion of Ibuprofen in Isolated Rat Hepatocytes," Drug Metab. Dispos. 18, 527-533, 1990.
`
`D.-H. Han, P. G. Pearson, T. A. Baillie, R. Dayal, L. H. Tsang and A. Gescher, "Chemical Synthesis and
`Cytotoxic Properties of N-Alkylcarbamic Acid Thioesters, Metabolites of Hepatotoxic Formamides,"
`Chem. Res. Toxicol. 3, 118-124, 1990.
`
`P. G. Pearson, J. G. Slatter, M. S. Rashed, D.-H. Han, M. P. Grillo and T. A. Baillie,
`"S-(N-Methylcarbamoyl)glutathione: A Reactive, S-Linked Metabolite of Methylisocyanate," Biochem.
`Biophys. Res. Commun. 166, 245-250, 1990.
`
`K.-J. Hoffmann, D. B. Axworthy and T. A. Baillie, "Mechanistic Studies on the Metabolic Activation of
`Acetaminophen In Vivo," Chem. Res. Toxicol. 3, 204-211, 1990.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11 of 38
`
`PENN EX. 2028
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`CURRICULUM VITAE
`Thomas A. Baillie
`
`Page 12
`
`R. A. Anderson, T. A. Baillie, M. Axelson, T. Cronholm, K. Sjövall and J. Sjövall, "Stable Isotope Studies on
`Steroid Metabolism and Kinetics. Sulfates of 3α-Hydroxy-5α-Pregnane Derivatives in Human
`Pregnancy," Steroids, 55, 443-457, 1990.
`
`
`R. H. Levy, A. W. Rettenmeier, G. D. Anderson, A. J. Wilensky, P. N. Friel, T. A. Baillie, A. Acheampong, J.
`Tor, M. Guyot and P. Loiseau, "Effects of Polytherapy with Phenytoin, Carbamazepine and Stiripentol on
`Formation of 4-Ene-Valproate, a Hepatoxic Metabolite of Valproic Acid," Clin. Pharmacol. Ther., 48,
`225-235, 1990.
`
`S. M. Sanins, W. J. Adams, D. G. Kaiser, G. W. Halstead, H. Barnes and T. A. Baillie, "Mechanistic Studies
`on the Metabolic Chiral Inversion of R(-)-Ibuprofen in the Rat," Drug Metab. Dispos., 19, 405-410, 1991.
`
`A. V. Boddy, K. Zhang, F. Lepage, F. Tombret, J. G. Slatter, T. A. Baillie and R. H. Levy, "In Vitro and In
`Vivo Investigations of Dihydro